FDA OKs letermovir for CMV prophylaxis in kidney transplant recipients

FDA has approved letermovir (Prevymis) for cytomegalovirus (CMV) prophylaxis in adult recipients of a CMV-seropositive kidney transplant. The new indication is based on results of a phase 3 clinical trial presented at the 2023 American Transplant Congress in San Diego, California and published in JAMA. Among adult CMV-seronegative kidney transplant recipients who received an organ from a CMV-seropositive donor, letermovir was noninferior to valganciclovir for prophylaxis of CMV disease over 52 weeks, with lower rates of leukopenia or neutropenia.